REL (REL proto-oncogene, NF-kB subunit)
The REL gene, also known as c-Rel, encodes a critical member of the NF-κB transcription factor family, which includes RelA (p65), RelB, p50, and p52. These proteins are characterized by a conserved Rel homology domain that mediates DNA binding, dimerization, and nuclear localization, enabling them to function as master regulators of immune and inflammatory responses. c-Rel is predominantly expressed in lymphoid tissues and immune cells, such as T cells, B cells, and macrophages, where it typically forms heterodimers with p50 or p65 to bind κB sites and drive the transcription of target genes involved in cell proliferation, survival, and cytokine production. By activating the expression of pro-inflammatory cytokines like IL-2 and IL-6, chemokines, and anti-apoptotic proteins from the Bcl-2 family, c-Rel plays a pivotal role in shaping adaptive immunity and preventing cell death. The activity of the NF-κB pathway, including c-Rel, is tightly controlled by upstream kinases such as the IKK complex and inhibited by IκB proteins, ensuring that responses to infection, stress, and cytokine stimulation are appropriately calibrated. Dysregulation of REL function has significant clinical implications; loss-of-function mutations or deletions, as seen in REL-knockout mice, result in severe T-cell activation defects and impaired antibody production, leading to immunodeficiency. Conversely, excessive c-Rel activity is associated with chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, and asthma, largely due to its role in promoting Th17 cell differentiation and sustained pro-inflammatory cytokine release. In oncology, REL amplification or overexpression is frequently observed in malignancies like diffuse large B-cell lymphoma, where it drives tumor progression by accelerating the cell cycle through the upregulation of cyclin D1 and conferring resistance to apoptosis induced by agents such as TNFα, thereby creating a delicate balance where therapeutic modulation must weigh the risks of immunosuppression against the dangers of uncontrolled inflammation or tumorigenesis.
Gene Ontology
Subcellular localization of REL (and its protein):
- plasma membrane
- cytoplasm
- extracellular
- golgi
- vesicle
- cytoskeleton
- endoplasmic reticulum
- nucleus
- endosome
- lysosome
- mitochondrion
Gene Ontology (GO) terms for REL:
| Interacting Gene | Interaction | Source/Score |
| Name |
|---|
| 4014 Ras signaling pathway [PATH:hsa04014] |
| 5202 Transcriptional misregulation in cancers [PATH:hsa05202] |
| 5203 Viral carcinogenesis [PATH:hsa05203] |
| Name |
|---|
| Activation of NF-kappaB in B cells |
| Adaptive Immune System |
| Downstream signaling events of B Cell Receptor (BCR) |
| Immune System |
| Signaling by the B Cell Receptor (BCR) |
| Disease | Score | NofPmids | NofSnps | Source |
| Rheumatoid Arthritis | 0.253192369 | 11 | 4 | BeFree_CTD_human_GAD_GWASCAT |
| Hodgkin Disease | 0.130540083 | 4 | 0 | CTD_human_GAD_LHGDN |
| Psoriasis | 0.123724241 | 6 | 0 | BeFree_CTD_human_GAD |
| Arthritis, Psoriatic | 0.123452799 | 4 | 1 | BeFree_GAD_GWASCAT |
| Inflammatory dermatosis | 0.12 | 1 | 1 | GWASCAT |
| Memory Disorders | 0.12 | 1 | 0 | CTD_human |
| Heat Stroke | 0.12 | 1 | 0 | CTD_human |
| B-Cell Lymphomas | 0.008977445 | 13 | 0 | BeFree_LHGDN |
| Lymphoma | 0.007348794 | 9 | 0 | BeFree_LHGDN |
| Celiac Disease | 0.004734064 | 2 | 2 | GAD |
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
